[Inhibition of prostaglandin synthesis during the therapy of nephrogenic diabetes insipidus].
A report is presented of a male infant with nephrogenic diabetes insipidus type I. A low-solute-load diet and large fluid intake were not able to prevent hypertonic dehydration and to control the disease. It responded within 3 days to indomethacin (3 mg/kg body weight), a prostaglandin synthetase inhibitor. The boy is doing well on this regimen and no side-effects have been observed after 2 years of treatment. Hitherto only a few case reports have been published on this therapeutic regimen, but all confirm the high efficacy of prostaglandin synthesis inhibition as the treatment of choice in nephrogenic diabetes insipidus.
D003919:Diabetes Insipidus / Q000628:therapy*; D003928:Diabetic Nephropathies / Q000628:therapy*; D005440:Fluid Therapy; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D011453:Prostaglandins / Q000096:biosynthesis*; D014667:Vasopressins
D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D014667:Vasopressins; D007213:Indomethacin
Prostaglandinsynthesehemmung in der Therapie des nephrogenen Diabetes insipidus.